Korea Institute of Science and Technology

Dae Hwa Pharma. Co., Ltd.

Neuroventi

University-Industry Cooperation Group of Kyung Hee University

Chan Young Shin

In Yong Jung

Dae Sik Jang

Hyun Ji Kim

Mee Kyung Song

Jae Chun Ryu

Jong Hoon Ryu

Hyung Eun Lee

Byeol Ryu

Ji-seong Yoon

Wooin Ryu

Yeong Woo Jo

Jae Hoon Cheong

Hyo Sun Lee

The present invention relates to a pharmaceutical composition for preventing or treating autism spectrum disorder, which includes piperazine-1-carboxamidine or a pharmaceutically acceptable salt thereof as an active ingredient. In particular, the piperazine-1-carboxamidine of the present invention exhibits, in valproic acid-induced autism rat models, an effect of improving the degrees of social interaction and social preference, reducing repetitive or restricted behaviors, hyperactivity, and impulsive behaviors, and also enhancing electroshock-induced seizure threshold susceptibility, and thus the piperazine-1-carboxamidine of the present invention may be used as an active ingredient of a pharmaceutical composition for preventing or treating direct causative symptoms, such as hyperactivity, lack of sociability, and epileptic convulsions of autism spectrum disorder.

Method of treating autism spectrum disorders using piperazine-1-carboxamidine or pharmaceutically acceptable salt thereof

The present invention provides a pharmaceutical composition or a food composition comprising, as active ingredients, flavone-6-C-glucose derivatives or galenical extracts containing flavone-6-C-glucose derivatives. The composition of the present invention shows a functional effect of effectively treating or preventing cognitive dysfunction disorders such as delirium, dementia or amnesia, stroke, palsy, attention disorders, anxiety disorders or sleep disorders.

Pharmaceutical composition for treating or preventing neuropsychiatric disease, containing flavone-6-C-glucose derivatives as active ingredients

The present invention relates to a biomarker for the identification of exposure to lower aliphatic saturated aldehydes by using micro RNA and a method for the identification of exposure to lower aliphatic saturated aldehydes using the same. In this invention, the micro RNA at least 1.5 fold up-regulated by exposure to lower aliphatic saturated aldehydes and the micro RNA up to 0.66 fold down-regulated by the same were selected. These two micro RNAs can be effectively used as the biomarker for the monitoring of lower aliphatic saturated aldehydes and for the risk assessment thereby and at the same time as a tool to investigate the mechanism of toxicity caused by such lower aliphatic saturated aldehydes.

Micro RNAs for identification of exposure to lower aliphatic saturated aldehydes and the method of identification using thereof

Growing community of inventors

Seoul, South Korea

Chan Young Shin